A new Phase III clinical trial highlights the significant efficacy of Dupilumab for CRSwNP in Chinese adult patients. Researchers recently published these findings in the journal Allergy, demonstrating that this monoclonal antibody provides a robust solution for those with inadequately controlled disease. Chronic rhinosinusitis with nasal polyps (CRSwNP) severely impacts patient quality of life, yet many fail to respond to standard intranasal corticosteroids.

During the study, investigators randomized 63 patients to receive either dupilumab 300 mg every two weeks or a placebo. Importantly, all participants continued their daily intranasal corticosteroid therapy as an add-on treatment. After 24 weeks, the results showed a clear clinical benefit for the intervention group.

The trial met its primary endpoint, showing a significant reduction in the Nasal Polyp Score (NPS) with dupilumab compared to placebo. Furthermore, patients experienced substantial relief from nasal congestion, which is a common and distressing symptom. Additionally, objective tests revealed a marked improvement in the sense of smell. Patients also reported better overall health-related quality of life, as measured by the SNOT-22 score.

Safety and Clinical Impact of Dupilumab for CRSwNP

Regarding safety, the drug was well-tolerated among the Chinese cohort. The most common adverse events included nasopharyngitis and injection site reactions, which aligns with previous international studies. No new safety concerns emerged during the 24-week period. Therefore, these results reinforce the global evidence supporting biologics in managing type 2 inflammatory airway diseases. This trial provides crucial data specifically for the Asian population, where such evidence was previously limited.

Frequently Asked Questions

What was the primary endpoint of the Chinese Phase III trial?

The primary endpoint was the change from baseline in the nasal polyp score (NPS) at week 24. The results showed a significant improvement in the dupilumab group compared to the placebo group.

What were the most common side effects observed in this study?

Common adverse events included nasopharyngitis and injection site reactions. These findings are consistent with the established safety profile of dupilumab in other global clinical trials.

Does Dupilumab improve the sense of smell in CRSwNP patients?

Yes, the study demonstrated a significant improvement in the University of Pennsylvania Smell Identification Test (UPSIT) scores for patients receiving dupilumab compared to those on placebo.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Xian M et al. Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo-Controlled, Phase III Trial. Allergy. 2026 Jun 16. doi: 10.1111/all.70414. PMID: 42299713.
2. ClinicalTrials.gov. Dupilumab in Chinese Adult Participants With CRSwNP. NCT05878093. Available at: https://clinicaltrials.gov/study/NCT05878093.
3. Han JK, et al. Efficacy and Safety of Dupilumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Results From the Randomized Phase 3. Presented at the 2019 Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).